MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial

Journal of the Neurological Sciences

Volumn 408, Issue , 2020, Pages

  Vogel, Andre C ^a   Okeng'o, Kigocha ^b   Chiwanga, Faraja ^b   Ismail, Seif Sharif ^b   Buma, Deus ^b   Pothier, Lindsay ^a   Mateen, Farrah J ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Africa; Fluoxetine; Ischemic stroke; Motor recovery; Neuroplasticity; Phase II clinical trial; Stroke

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CREATININE; FLUOXETINE; PLACEBO; POTASSIUM; SODIUM; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFRICA SOUTH OF THE SAHARA; AFRICAN; ARTICLE; BEHAVIOR; BRAIN ISCHEMIA; COMORBIDITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOBILIZATION; MORBIDITY; MOTOR PERFORMANCE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT HEALTH QUESTIONNAIRE; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; POPULATION; PREVALENCE; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; STROKE PATIENT; STROKE SURVIVOR; TANZANIA; TREATMENT DURATION; VIRUS LOAD; WORLD HEALTH ORGANIZATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WALKING;

BRAIN ISCHEMIA; FEMALE; FLUOXETINE; HUMANS; MALE; MOTOR ACTIVITY; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; STROKE; TANZANIA; TREATMENT OUTCOME; WALKING;

EID: 85074693597     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2019.116563     Document Type: Article

References (33)

1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16 (2017), 877–897.
2. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:10100 (2017), 1260–1344.
3. Walker, R.W., Viney, R., Green, L., et al. Trends in stroke admissions to a Tanzanian hospital over four decades: a retrospective audit. Tropical Med. Int. Health 20 (2015), 1290–1296.
4. Stenumgård, P.S., Rakotondranaivo, M.J., Sletvold, O., et al. Stroke in a resource-constrained hospital in Madagascar. BMC Res. Notes, 10, 2017, 307.
5. Ezejimofor, M.C., Uthman, O.A., Maduka, O., et al. Stroke survivors in Nigeria: a door-to-door prevalence survey from the Niger Delta region. J. Neurol. Sci. 372 (2017), 262–269.
6. Leys, D., Henon, H., Mackowiak-Cordoliani, M.-A., Pasquier, F., Poststroke Dementia. Lancet Neurol. 4 (2005), 752–759.
7. Norrving, B., Kissela, B., The global burden of stroke and need for a continuum of care. Neurology. 80:3 (2013), S5–S12.
8. Guerchet, M., Akinyemi, R., Paddick, S.M., Wimo, A., Prince, M., Alzheimer's Disease International, The epidemiological evidence: prevalence, costs, incidence, mortality and risk factors. Dementia in Sub-Saharan Africa: Challenges and Opportunities (16–40), 2017 Sept, Alzheimer's Disease International.
9. Lee, J.Y., Lee, H.E., Kang, S.R., et al. Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood-brain barrier disruption. Neuropharmacology 79 (2014), 161–171.
10. Ng, K.L., Gibson, E.M., Hubbard, R., et al. Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model. Stroke 46 (2015), 2951–2960.
11. Fruehwald, S., Gatterbauer, E., Rehak, P., et al. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. J. Neurol. 250 (2003), 347–351.
12. Chollet, F., Tardy, J., Albucher, J.-F., et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 10 (2011), 123–130.
13. Gladstone, D.J., Danells, C.J., Black, S.E., The Fugl-Meyer assessment of motor recovery after stroke: a critical review of its measurement properties. Neurorehabil. Neural Repair 16 (2002), 232–240.
14. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 393 (2019), 265–274.
15. Regenhardt, R.W., Biseko, M.R., Shayo, A.F., et al. Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania. Int. J. Qual. Health Care 31 (2019), 385–392.
16. Adams, H.P.J., Bendixen, B.H., Kapelle, L.J., et al. Classifications of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 24 (1993), 35–41.
17. Saadi, A., Okeng'o, K., Biseko, M.R., et al. Post-stroke social networks, depressive symptoms, and disability in Tanzania: a prospective study. Int. J. Stroke 13 (2018), 840–848.
18. Palli, C., Fandler, S., Doppelhofer, K., et al. Early dysphagia screening by trained nurses reduces pneumonia rate in stroke patients: a clinical intervention study. Stroke 48 (2017), 2583–2585.
19. Pillsy | 24x7 Digital Medication Coach, with Smart Pill Bottle and App [Internet]. Available from https://www.pillsy.com/.
20. Kroenke, K., Spitzer, R.L., Williams, J.B.W., The PHQ-9. J. Gen. Intern. Med. 16 (2001), 606–613.
21. Montgomery, S.A., Åsberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979), 382–389.
22. Okeng'o, K., Chillo, P., Gray, W.K., Walker, R.W., Matuja, W., Early mortality and associated factors among patients with stroke admitted to a large teaching hospital in Tanzania. J. Stroke Cerebrovasc. Dis. 26:4 (2017), 871–878.
23. Mead, G., Hackett, M.L., Lundström, E., et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials., 20(16), 2015, 369.
24. Weimar, C., Ziegler, A., König, I.R., Diener, H.C., Predicting functional outcome and survival after acute ischemic stroke. J. Neurol. 249:7 (2002), 888–895.
25. Appelros, P., Nydevik, I., Viitanen, M., Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke. 34:1 (2003 Jan), 122–126.
26. Spriggs, M.J., Cadwallader, C.J., Hamm, J.P., Tippett, L.J., Kirk, I.J., Age-related alterations in human neocortical plasticity. Brain Res. Bull. 130 (2017), 53–59.
27. Pinto, C.B., Saleh Velez, F.G., Lopes, F., et al. SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus. Front. Neurosci., 11, 2017, 637.
28. Kraus, C., Castrén, E., Kasper, S., Lanzenberger, R., Serotonin and neuroplasticity - links between molecular, functional and structural pathophysiology in depression. Neurosci. Biobehav. Rev. 77 (2017), 317–326.
29. Sacktor, N., Skolasky, R.L., R3, M., et al. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. J. Neuro-Oncol. 24:1 (2018), 16–27.
30. Ances, B.M., Letendre, S.L., Alexander, T., Ellis, R.J., Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int. Rev. Psychiatr. 20:1 (2008), 89–93.
31. Berkowitz, A.L., Mittal, M.K., McLane, H.C., et al. Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke. Int. J. Stroke 9 (2014), 349–355.
32. Stewart, J.C., Cramer, S.C., Genetic variation and neuroplasticity: role in rehabilitation after stroke. J. Neurol. Phys. Ther. 41:Suppl. 3 (2017), S17–S23.
33. Alawieh, A., Zhao, J., Feng, W., Factors affecting post-stroke motor recovery: implications on neurotherapy after brain injury. Behav. Brain Res. 340 (2018), 94–101.